FDA Panel Favors Nixing Avastin For Breast Cancer
A U.S. Food and Drug Administration advisory committee has recommended revoking approval of Genentech Inc.'s blockbuster cancer drug Avastin for use in breast cancer patients, saying the product may not help...To view the full article, register now.
Already a subscriber? Click here to view full article